CN114146090A - New application of apilimod as coronavirus broad-spectrum inhibitor - Google Patents
New application of apilimod as coronavirus broad-spectrum inhibitor Download PDFInfo
- Publication number
- CN114146090A CN114146090A CN202010915364.8A CN202010915364A CN114146090A CN 114146090 A CN114146090 A CN 114146090A CN 202010915364 A CN202010915364 A CN 202010915364A CN 114146090 A CN114146090 A CN 114146090A
- Authority
- CN
- China
- Prior art keywords
- coronavirus
- apilimod
- virus
- pneumonia
- sars
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229950002889 apilimod Drugs 0.000 title claims abstract description 65
- HSKAZIJJKRAJAV-KOEQRZSOSA-N n-[(e)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine Chemical compound CC1=CC=CC(\C=N\NC=2N=C(OCCC=3N=CC=CC=3)N=C(C=2)N2CCOCC2)=C1 HSKAZIJJKRAJAV-KOEQRZSOSA-N 0.000 title claims abstract description 65
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 31
- 239000003112 inhibitor Substances 0.000 title abstract description 7
- 208000001528 Coronaviridae Infections Diseases 0.000 claims abstract description 29
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 28
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims abstract description 19
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 17
- 208000025370 Middle East respiratory syndrome Diseases 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 9
- 201000009240 nasopharyngitis Diseases 0.000 claims abstract description 7
- 241001428935 Human coronavirus OC43 Species 0.000 claims abstract description 6
- 101800000904 Spike protein S1 Proteins 0.000 claims abstract description 4
- 241000315672 SARS coronavirus Species 0.000 claims description 14
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 13
- 241000711467 Human coronavirus 229E Species 0.000 claims description 5
- 241000482741 Human coronavirus NL63 Species 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 241001109669 Human coronavirus HKU1 Species 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 208000025721 COVID-19 Diseases 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 24
- 208000015181 infectious disease Diseases 0.000 abstract description 7
- 230000000903 blocking effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 15
- 241000711975 Vesicular stomatitis virus Species 0.000 description 10
- 229940096437 Protein S Drugs 0.000 description 9
- 101710198474 Spike protein Proteins 0.000 description 9
- 241001112090 Pseudovirus Species 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 102100031673 Corneodesmosin Human genes 0.000 description 6
- 101710139375 Corneodesmosin Proteins 0.000 description 6
- 101001028244 Onchocerca volvulus Fatty-acid and retinol-binding protein 1 Proteins 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 4
- 108091005609 SARS-CoV-2 Spike Subunit S1 Proteins 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000003032 molecular docking Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 101710116435 Outer membrane protein Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102100038028 1-phosphatidylinositol 3-phosphate 5-kinase Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 101710145421 1-phosphatidylinositol 3-phosphate 5-kinase Proteins 0.000 description 1
- 108040005121 1-phosphatidylinositol-4-phosphate 5-kinase activity proteins Proteins 0.000 description 1
- 102000032155 1-phosphatidylinositol-5-phosphate 4-kinase activity proteins Human genes 0.000 description 1
- 108040005122 1-phosphatidylinositol-5-phosphate 4-kinase activity proteins Proteins 0.000 description 1
- 101800000535 3C-like proteinase Proteins 0.000 description 1
- 101800002396 3C-like proteinase nsp5 Proteins 0.000 description 1
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 101100028391 Arabidopsis thaliana PI4KB1 gene Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 241000283966 Pholidota <mammal> Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241001068295 Replication defective viruses Species 0.000 description 1
- 101150010882 S gene Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 235000012511 Vaccinium Nutrition 0.000 description 1
- 241000736767 Vaccinium Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940127002 anti-2019-nCov Drugs 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 108700010904 coronavirus proteins Proteins 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 101150044508 key gene Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- -1 small molecule compound Chemical class 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000003041 virtual screening Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a new application of apilimod, wherein apilimod is used as a broad-spectrum inhibitor of coronavirus for treating 2019 novel coronavirus, Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS) pneumonia infection and common cold caused by human coronavirus OC43(HCoV-OC 43). Apilimod can bind to spike protein S1 of coronavirus, affecting the virus-binding receptor, thereby blocking the virus from entering cells. The apilimod is used as a new old medicine, has no problem on the safety, and therefore can be applied to clinic.
Description
Technical Field
The invention belongs to the field of medicines, relates to a new application of apilimod, and particularly relates to an application of apilimod in treatment of coronavirus infection.
Background
Highly pathogenic coronavirus infection has become a public health concern over the last decade. Severe acute respiratory syndrome (SARS, 2002-2004), middle east respiratory syndrome (MERS, 2012-to-date), 2019 novel coronavirus 2019-nCoV (COVID-19), each of which has a tremendous impact on human health and economic development.
Because there are no effective drugs and vaccines, the research and development of new drugs for new coronavirus is of great significance, and in the war without smoke, a plurality of scientific research institutions and pharmaceutical companies around the world are dedicated to research and develop new coronavirus vaccines and therapeutic drugs. The invention in the field has great social and economic significance.
Apilimod, apilimimod, is a small molecule compound with cell permeability that inhibits PIKfyve with an IC50 of 14nM, for the treatment of autoimmune diseases such as crohn's disease. It is also an IL-12/23 inhibitor and is inactive against other lipid kinases and protein kinases such as PIP4K, PIP5K, mTOR, PI3K and PI4K subtypes.
Disclosure of Invention
The invention aims to provide an effective inhibitor of coronavirus including 2019 novel coronavirus (COVID-19), and can prevent and treat coronavirus infection including 2019 novel coronavirus. The invention provides a new application of apilimod, which is an effective inhibitor of coronavirus including 2019 novel coronavirus, and an application of the apilimod in preparation of a medicament for preventing or treating coronavirus infection.
The application is that the coronavirus comprises 2019 novel coronavirus (COVID-19), Severe Acute Respiratory Syndrome (SARS) virus, Middle East Respiratory Syndrome (MERS) virus, common cold human coronavirus OC43(HCoV-OC43), human coronavirus NL63(HCoV-NL63), human coronavirus 229E (HCoV-229E) and human coronavirus HKU1(HCoV-HKU 1).
The application, wherein the coronavirus is 2019 novel coronavirus (COVID-19).
The use wherein the coronavirus infection is coronavirus pneumonia or common cold.
The application is characterized in that the coronavirus infection comprises 2019 novel coronavirus COVID-19 pneumonia, severe acute respiratory syndrome SARS, middle east respiratory syndrome MERS, human coronavirus OC43 pneumonia, human coronavirus NL63 pneumonia, human coronavirus 229E pneumonia, human coronavirus HKU1 pneumonia and common cold.
The use of (b), wherein the coronavirus infection is 2019 novel coronavirus pneumonia.
The inventors have found a new use of apilimod through a great deal of research, wherein apilimod can bind 2019 spike protein S1 of a novel coronavirus, so as to block the virus from entering cells, and the apilimod is EC 50-86 nM, CC 50-47.39 uM, and SI-551 at the cellular level.
2019 the novel coronavirus enters the cell and recognizes the receptor ACE2 by the spike protein spike, so that the small molecule inhibitor taking the spike protein as a target can be applied to the treatment of the novel coronavirus.
The inventors also found that apilimod binds equally well to the S1 target protein of SARS and MERS. Therefore, apilimod can be applied to the treatment of the coronavirus infection of the subtypes.
The compounds of the present invention may be formulated into various suitable pharmaceutical preparation forms. Can be used alone or mixed with medicinal adjuvants (such as excipient, diluent, etc.) to make into oral tablet, capsule, granule or syrup, or powder for injection or solution.
Compared with the prior art, the invention has the following technical effects:
apilimod can bind with spike protein S1 at cellular level, prevent virus from entering cells, and treat coronavirus pneumonia infection and common cold, and inhibit EC50 of GX-P2V coronavirus to 86 nM.
The inventor finds that the apilimod can not inhibit vesicular stomatitis virus VSV, and proves that the apilimod can inhibit coronavirus and Spike protein Spike are related.
Drawings
FIG. 1 prediction of SARS-CoV-2S 1& apilimod binding site
Figure 1 shows AI predicted binding sites for apilimod and 2019 novel coronavirus S1 protein.
FIG. 2 prediction of SARS-CoV S1& apilimod binding site
FIG. 2 shows AI-predicted binding sites for apilimod and SARS coronavirus S1 proteins.
FIG. 3 prediction of MERS-CoV S1& apilimod binding site
Fig. 3 shows AI predicted binding sites for apilimod and MERS coronavirus S1 proteins.
FIG. 4 SARS-CoV-2S 1& apilimod sensorgram
Figure 4 shows the affinity of apilimod and 2019 novel coronavirus S1 protein.
FIG. 5 SARS S1& apilimod sensorgram
Figure 5 shows the affinity of apilimod and SARS virus S1 protein.
FIG. 6, MERS S S1+ S2 ECD & apilimod sensing diagram
Figure 6 shows the affinity of apilimod and MERS virus S1+ S2 ECD proteins.
FIG. 7, OC 43S 1+ S2 ECD & apilimod sensing diagram
Figure 7 shows the affinity of apilimod and OC43 virus S1+ S2 ECD proteins.
FIG. 8, NL 63S 1+ S2 ECD & apilimod sensorgram
Figure 8 shows the affinity of apilimod and NL-63 virus S1+ S2 ECD proteins.
FIG. 9, HKU-1S1+ S2 ECD & apilimod sensorgram
FIG. 9 shows the affinity of apilimod and HKU-1 virus S1+ S2 ECD proteins.
FIG. 10. apilimod inhibits SARS-CoV-2 pseudovirus entry into cells
FIG. 11, the inhibition of SARS-CoV pseudovirus entry into cells by apilimod
FIG. 12. EC of apilimod in inhibiting MERS-CoV virus50
FIG. 13 EC of apilimod in inhibiting NL63-CoV Virus50
FIG. 14, the EC of apilimod for inhibiting GX-P2V virus50And CC50
FIG. 15. the inability of apilimod to inhibit VSV Virus
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
The technical scheme of the present invention will be further described below with reference to specific experimental operations and data.
The inhibitory effect of apilimod on various subtypes of coronavirus is demonstrated by the following experiments. Sources of apilimod: purchased from selechchemicals, cat # S (S6414).
Example 1AI predicted binding site
The SARS-CoV-2spike protein (PDB: 6vw1) was downloaded from PDB (http:// www.rcsb.org /); SARS spike protein (pdb: 2dd 8); MERS spike protein (pdb: 6c6 z). All foreign atoms and spike ligands are removed. The Mpro docking grid is maximized for apilimod docking. The PDB file is converted to macromolecules in the PDBQT format prior to virtual screening. The position of the grid (ligand docking search space) is as described above. Then, Autodock Vina 1.1.2 was used for subsequent molecular docking. Using Pymol version 1.7.4.5 it was possible to observe protein binding toThe interaction of the ligands. spike protein proximity hit ligandsAre highlighted as potential interaction residues involved in protein-ligand interactions. The results are shown in FIGS. 1-3.
The experimental results are as follows:
the binding sites of apimod and SARS-CoV-2spike protein are VAL341, ALA344, PHE347, ALA348, SER349, TRP353, ASN354, ARG355, SER 399.
Binding sites of apilimo and SARS-CoV spike protein are PHE325, GLY326, PHE329, ASN330, ASP351, VAL354, LEU355, SER358, PHE 360.
Binding sites of apilimo and MERS-CoV spike protein are LYS502, SER504, PHE506, GLU513, PRO515, TYR540, VAL 555.
Example 2 coronavirus S protein SPR experiment
Experimental materials and instruments
biacore T200(GE healthcare, Uppsala, Sweden), CM5 chip (GE healthcare, Uppsala, Sweden), apilimod (select chemicals), 2019-CoV S1 protein (yinqian), SARS S1 protein (yinqian), MERS S1+ S2 ECD protein (yinqian), OC 43S 1+ S2 ECD protein (yinqian), NL 63S 1+ S2 ECD protein (yinqian), HKU-1S1+ S2 ECD protein (yinqian).
Model is biacore T200 of GE company, and S1 protein (Yiqian Shenzhou), SARS virus S protein (Yiqian Shenzhou), MERS virus S1+ S2 ECD protein (Yiqian Shenzhou), OC 43S 1+ S2 ECD protein (Yiqian Shenzhou), NL 63S 1+ S2 ECD protein (Yiqian Shenzhou), HKU-1S1+ S2 ECD protein (Yiqian Shenzhou) are coupled to a CM5 chip through amino groups, the coupling amounts are 9499.3RU,13628.8RU 14187.7RU,6082.3RU,14602.8RU,16061.2RU, and the affinities of the apilimod and the S protein at 25 ℃ are measured. Apilimod was injected at a flow rate of 30 μ L/min at concentrations of 100uM,50uM,25uM,12.5uM,6.25uM,3.125uM, 1.5625uM,0.78125uM,0uM for a sample injection time of 180s and a dissociation time of 300 s. The data analysis mode is steady state analysis. The results are shown in FIGS. 4-9. The SPR results are summarized in table 1 below.
TABLE 1 affinity of apilimod for binding to the S protein of various subtypes of coronavirus at 25 ℃
Protein | KD(M) | Rmax(RU) | Chi2(RU2) | chi |
2019CoV S1 | 2.739*10-6 | 19.4 | 3.32 | 1.82 |
SARS S1 | 3.22*10-5 | 42.63 | 0.813 | 0.901 |
MERS S1+S2 | 1.029*10-4 | 129.8 | 3.43 | 1.85 |
OC43 S1+S2 | 9.829*10-5 | 76.31 | 2.19 | 1.48 |
NL63 S1+S2 | 7.497*10-5 | 119.3 | 9.04 | 3.01 |
HKU-1 S1+S2 | 7.155*10-6 | 46.98 | 3.76 | 1.94 |
Example 3
VSV-dG-fLuc replication-deficient pseudovirus infection experiment of coronavirus outer membrane-detection of Effect of apilimod in inhibiting coronavirus entry into cells
Experimental Material
VSV-dG-GFP, in which the glycoprotein (G) of VSV is replaced by GFP fluorescent protein. A pseudoviral packaging system for VSV-dG-fLuc (Firefo luciferase) Vesicular Stomatitis Virus (VSV) was obtained from reverse genetics plasmid rescue (Rescue), and the relevant plasmids were purchased from Karafast. Wherein pVSV- Δ G-Luciferase is used for transcription replication-deficient recombinant VSV genomes, wherein the glycoprotein (G) of VSV is replaced by Firefly Luciferase (fLuc), and pBS-N, pBS-P, pBS-L, pBS-G is used as an auxiliary vector to aid in first round of virus rescue.
Rescue and amplification of VSV-dG-fLuc replication-defective viruses containing the VSVG outer Membrane
BHK21 cells were attached to 3.5cm dish, and the next day when the cells reached 90% density, and infected with a poxvirus recombinantly expressing T7 RNA polymerase (Vaccinium virus-T7, vv-T7) at a titer of MOI ═ 5 (DMEM, serum-free) for 45 minutes at 37 ℃. After washing the cells once with PBS, the cells that had been infected with vv-T7 were transfected with the mixed reverse genetics plasmid (pVSV-. DELTA.G-Luciferase: pBS-N: pBS-P: pBS-G: pBS-L ═ 5:3:5:8:1) transfected with Lipo3000, the solution was changed after 12 hours, the supernatant containing the primary VSV-dG-fLuc virus was collected after 48 hours, and the residual vv-T7 was removed by filtration through a 0.22 μm filter. To further amplify the virus, HEK293T cells were transfected with pMD2.G overexpressing VSV G protein (ATCC: Plasmid #12259), 24 hours later, primary supernatants were combined with DMEM + 10% serum 1: 1 for infection, collecting the supernatant after 24-48 hours, centrifuging at 12000 rpm for 2 minutes, retaining the supernatant and packaging, determining the virus titer by plaque method, and storing at-80 ℃.
Packaging VSV-dG-fLuc replication-deficient pseudovirus containing coronavirus SARS-CoV-2, SARS-CoV, MERS-CoV, NL63-CoV outer membrane
HEK293T cells or Vero-E6 cells were transfected with plasmids overexpressing the SARS-CoV-2, SARS-CoV, MERS-CoV, NL63-CoV outer membrane proteins (pCAGGS-SARS-2-S-dc) (pCAGGS-SARS-S-dc). After 24 hours, the transfected cells were infected with VSV-dG-ffluc virus containing the VSVG outer membrane at MOI ═ 10 (1:30 dilution) for 1 hour at 37 ℃, followed by addition of a solution containing 1: DMEM + 10% FBS medium with 300 dilutions of rat anti-VSVG antiserum was used to completely neutralize residual VSV-dG-fLuc pseudovirus containing the VSVG outer membrane. The virus-containing supernatants were harvested after 24-48 hours, centrifuged at 12000 rpm for 2 minutes, retained and aliquoted, assayed for viral titer by CPE using limiting dilution (Infections Unit) and stored at-80 ℃.
Determination of half effective depth of drug by infection with SARS-CoV-2, SARS-CoV, MERS-CoV and NL63-CoV pseudoviruses based on VSV (EC50)
BHK21-ACE2 cells (Wuhan Dai selection) were attached to 96-well plates. After 24 hours, the cell density reached about 90%, and different concentrations of the drug were mixed with different pseudoviruses, such as VSV-dG pseudovirus expressing GFP or Fluc containing VSVG outer membrane protein or SARS-CoV-2/SARS-CoV/MERS-CoV outer membrane protein (MOI ═ 0.1), respectively, in a DMEM + 10% FBS medium, and then the cells were infected. After 24 hours, cells expressing GFP after infection were photographed by fluorescence microscopy; or to measure intracellular fluoresceinEnzyme intensity, the culture supernatant was removed, 20. mu.l of 1 XPassive lysine buffer (Promega) was added, and the mixture was left at room temperature for 10 minutes and passed through One-Glo luciferase kit (Promega) and20/20 bioluminescence assay apparatus (Promega). Cytotoxicity was observed by microscopic bright field. The results are shown in FIGS. 10-13.
Example 4GX-P2V coronavirus infection assay to examine the Effect of apilimod on inhibiting coronavirus replication
The detection principle is that GX-P2V is highly homologous with SARS-CoV-2, and the comparison analysis of the whole genome and each virus coding gene (nucleotide level and amino acid level) shows that: GX-P2V is highly homologous with SARS-CoV-2, the homology with S protein of SARS-CoV-2 is 92.5%, it is the virus which has the highest homology with S protein of SARS-CoV-2 and is successfully isolated and cultured so far, no matter it is whole genome level or the key gene S gene of virus adsorbed into cell, the homology of GX P2V and SARS-CoV-2 is far higher than SARS virus, see Table 2.
TABLE 2GX P2V comparison of nucleic acid and amino acid homologies with other coronaviruses
#Wuhan-Hu-1 SARS-CoV-2(NC_045512.2)was used for comparison with Bat-Cov Ra TG13(EPI_ISL_402132),Guangdong pangolin Cov(merged of GD/PIL and GD/P2S),and Guangxi pangolinCoV(GX/P5L)
*partial sequence
A substitution model of 2019-nCoV is used, so that the risk and the complexity of operating experiments in a P3 laboratory are avoided. The GX P2V virus used by the people can be cultured in a common P2 laboratory, can be used as an ideal anti-2019-nCoV virus substitution model, and a large number of basic experiments can be verified by the 2019-nCoV virus after being explored on the virus model.
Experimental materials and instruments:
cell: vero E6, manufacturer ATCC
Virus: GX-P2V virus, North chemical industry of manufacturers
Sample preparation: aripimod, vendor select chemicals, concentration 10mM, storage conditions-20 degrees
Detection reagent:
TABLE 3 detection reagents
EC50 and CC50 studies on inhibition of GX-P2V by apilimod
1) Culture of cells
Vero E6 cells (ATCC) were cultured with high-glucose DMEM + 10% fetal bovine serum. Cells were cultured at 1.5X104Density of/well was seeded in 96-well plates (Thermo Fisher) or 8X104Density per well was inoculated into 24-well plates and incubated at 37 ℃ in a 5% CO2 incubator.
2) Determination of semi-effective concentration EC50 of apilimod
Vero E6 cells were seeded into 24-well plates, the next day, the cells were infected with GX-P2V virus and 2-fold dilutions of the compound (100 uM max) were added, after 2h the supernatant was aspirated off and washed with PBS buffer, followed by 2-fold dilutions of the drug (100 uM max). 37 ℃ and 5% CO2The incubator was incubated for 72 hours. QRT-PCR was used to detect viral copy number. The value of EC50 was determined using non-linear regression.
3) Confirmation of EC50 and CC50 of apilimod inhibiting GX-P2V
Vero E6 cells were seeded into 24-well plates, and the next day, 0.195,0.39,0.78,1.56,3.12,6.24,12.5,25,5 and 100. mu.M apilimod was added to the cells, respectively, followed by the virus. After 2 hours, the supernatant was removed by changing the solution, and washed with PBS buffer to remove virus particles that did not enter the cells, and then the cells were added with apilimod again at 0.195,0.39,0.78,1.56,3.12,6.24,12.5,25,5 and 100 μ M. The copy number of the viral RNA in the cells was quantified by qRT-PCR 72h after viral infection and normalized with GAPDH levels. The cytotoxicity of the drug to vero E6 was measured using the CellTiter-Blue Activity assay.
The result is shown in figure 14, the low-concentration apilimod can obviously inhibit GX-P2V, and the EC50, CC50 and SI of the apilimod on GX-P2V are 86nM, 47.39 mu M and 551 respectively, and the data show that the apilimod has good effect on resisting coronavirus GX P2V and has potential for clinically treating coronavirus infection.
Example 5
Apilimod cannot inhibit vesicular stomatitis virus VSV, demonstrating that apilimod inhibition of coronavirus is associated with Spike protein Spike. See fig. 15.
Claims (10)
1. Application of apilimod in preparing medicine for preventing and treating coronavirus infection.
2. Use according to claim 1, characterized in that: the coronavirus comprises 2019 novel coronavirus COVID-19, severe acute respiratory syndrome SARS virus, middle east respiratory syndrome MERS virus, human coronavirus HCoV-OC43, human coronavirus NL63, human coronavirus 229E and human coronavirus HKU 1.
3. Use according to claim 1, characterized in that: the coronavirus includes 2019 novel coronavirus COVID-19, severe acute respiratory syndrome SARS virus and middle east respiratory syndrome MERS virus.
4. Use according to claim 1, characterized in that: the coronavirus is a 2019 novel coronavirus COVID-19.
5. Use according to any one of claims 1 to 4, characterized in that: the coronavirus infection is coronavirus pneumonia or common cold.
6. Use according to any one of claims 1-2, characterized in that: the coronavirus infection comprises 2019 novel coronavirus COVID-19 pneumonia, severe acute respiratory syndrome SARS, middle east respiratory syndrome MERS, human coronavirus HCoV-OC43 pneumonia, human coronavirus NL63 pneumonia, human coronavirus 229E pneumonia, human coronavirus HKU1 pneumonia and common cold.
7. Use according to any one of claims 1 to 3, characterized in that: the coronavirus infection comprises 2019 novel coronavirus COVID-19 pneumonia, severe acute respiratory syndrome SARS and middle east respiratory syndrome MERS.
8. Use according to any one of claims 1 to 4, characterized in that: the coronavirus infection is 2019 novel coronavirus COVID-19 pneumonia.
9. Use according to any one of claims 1 to 4, characterized in that: apilimod binds to spike protein S1 of coronavirus.
10. Use according to claim 1, characterized in that: when in use, the oral preparation is adopted, and the oral preparation contains the apilimod with effective treatment amount and pharmaceutically acceptable carrier auxiliary materials for preparing the oral preparation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010915364.8A CN114146090A (en) | 2020-09-08 | 2020-09-08 | New application of apilimod as coronavirus broad-spectrum inhibitor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010915364.8A CN114146090A (en) | 2020-09-08 | 2020-09-08 | New application of apilimod as coronavirus broad-spectrum inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114146090A true CN114146090A (en) | 2022-03-08 |
Family
ID=80460189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010915364.8A Pending CN114146090A (en) | 2020-09-08 | 2020-09-08 | New application of apilimod as coronavirus broad-spectrum inhibitor |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114146090A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111759841A (en) * | 2020-06-03 | 2020-10-13 | 山西第三医学研究发展有限公司 | Application of pidotimod in resisting novel coronavirus infection |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1460474A (en) * | 2003-07-08 | 2003-12-10 | 中国医学科学院医药生物技术研究所 | Application of geldanamycin in preparation of medicine for curing SARS |
CN106074506A (en) * | 2016-06-13 | 2016-11-09 | 广州医科大学附属第医院 | The application that arbidol hydrochloride prevents in preparation and treats in the medicine of anti-Middle East respiratory system syndrome coronavirus |
CN111544442A (en) * | 2020-06-02 | 2020-08-18 | 华北制药集团新药研究开发有限责任公司 | New use of rutin as coronavirus broad-spectrum inhibitor |
-
2020
- 2020-09-08 CN CN202010915364.8A patent/CN114146090A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1460474A (en) * | 2003-07-08 | 2003-12-10 | 中国医学科学院医药生物技术研究所 | Application of geldanamycin in preparation of medicine for curing SARS |
CN106074506A (en) * | 2016-06-13 | 2016-11-09 | 广州医科大学附属第医院 | The application that arbidol hydrochloride prevents in preparation and treats in the medicine of anti-Middle East respiratory system syndrome coronavirus |
CN111544442A (en) * | 2020-06-02 | 2020-08-18 | 华北制药集团新药研究开发有限责任公司 | New use of rutin as coronavirus broad-spectrum inhibitor |
Non-Patent Citations (1)
Title |
---|
YUAN-LIN KANG ET AL.: "Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2", 《PNAS》, 25 August 2020 (2020-08-25), pages 20803 - 20813, XP055801336, DOI: 10.1073/pnas.2007837117 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111759841A (en) * | 2020-06-03 | 2020-10-13 | 山西第三医学研究发展有限公司 | Application of pidotimod in resisting novel coronavirus infection |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Boopathi et al. | Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment | |
Zhang et al. | Understanding the role of SARS-CoV-2 ORF3a in viral pathogenesis and COVID-19 | |
Larue et al. | Rationally designed ACE2-derived peptides inhibit SARS-CoV-2 | |
Musarrat et al. | The anti‐HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV‐2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID‐19 infections | |
Senapati et al. | Contributions of human ACE2 and TMPRSS2 in determining host–pathogen interaction of COVID-19 | |
Wu et al. | Severe acute respiratory syndrome coronavirus 2: from gene structure to pathogenic mechanisms and potential therapy | |
Robinson et al. | Predicting the next eye pathogen: analysis of a novel adenovirus | |
Yang et al. | Inhibitory effect on SARS‐CoV‐2 infection of neferine by blocking Ca2+‐dependent membrane fusion | |
Yang et al. | Drug repurposing of itraconazole and estradiol benzoate against COVID‐19 by blocking SARS‐CoV‐2 spike protein‐mediated membrane fusion | |
Saville et al. | Three-dimensional visualization of viral structure, entry, and replication underlying the spread of SARS-CoV-2 | |
Rosendal et al. | Serine protease inhibitors restrict host susceptibility to SARS-CoV-2 infections | |
Han et al. | Advances and challenges in the prevention and treatment of COVID-19 | |
Wędrowska et al. | Coronaviruses fusion with the membrane and entry to the host cell | |
Manhas et al. | Covid-19 pandemic and current medical interventions | |
Hashizume et al. | Phenothiazines inhibit SARS-CoV-2 cell entry via a blockade of spike protein binding to neuropilin-1 | |
Kumar et al. | A review of novel coronavirus disease (COVID-19): based on genomic structure, phylogeny, current shreds of evidence, candidate vaccines, and drug repurposing | |
Gong et al. | COVID-19: A state of art on immunological responses, mutations, and treatment modalities in riposte | |
Wang et al. | Human endeavor for anti-SARS-CoV-2 pharmacotherapy: a major strategy to fight the pandemic | |
Wang et al. | Recent progress of surface plasmon resonance in the development of coronavirus disease-2019 drug candidates | |
Buchwald | Developing small-molecule inhibitors of protein-protein interactions involved in viral entry as potential antivirals for COVID-19 | |
Septisetyani et al. | SARS-CoV-2 antibody neutralization assay platforms based on epitopes sources: Live virus, pseudovirus, and recombinant S glycoprotein RBD | |
CN114146090A (en) | New application of apilimod as coronavirus broad-spectrum inhibitor | |
Gupta | Progress in studies on structural and remedial aspects of newly born coronavirus, SARS-CoV-2 | |
Raj et al. | Current understanding on molecular drug targets and emerging treatment strategy for novel coronavirus-19 | |
Ma et al. | Teicoplanin derivatives block spike protein mediated viral entry as pan-SARS-CoV-2 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |